Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.629,21
    -107,19 (-0,32%)
     

  • Dow Jones

    38.675,68
    +450,02 (+1,18%)
     

  • Nasdaq

    16.156,33
    +315,37 (+1,99%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • Petrolio

    77,99
    -0,96 (-1,22%)
     

  • Bitcoin EUR

    59.458,79
    +1.845,80 (+3,20%)
     

  • CMC Crypto 200

    1.359,39
    +82,41 (+6,45%)
     

  • Oro

    2.310,10
    +0,50 (+0,02%)
     

  • EUR/USD

    1,0765
    +0,0038 (+0,36%)
     

  • S&P 500

    5.127,79
    +63,59 (+1,26%)
     

  • HANG SENG

    18.475,92
    +268,79 (+1,48%)
     

  • Euro Stoxx 50

    4.921,48
    +30,87 (+0,63%)
     

  • EUR/GBP

    0,8577
    +0,0023 (+0,27%)
     

  • EUR/CHF

    0,9735
    -0,0024 (-0,25%)
     

  • EUR/CAD

    1,4726
    +0,0064 (+0,44%)
     

Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

Cara Therapeutics, Inc.
·1 minuto per la lettura
Cara Therapeutics, Inc.
Cara Therapeutics, Inc.

STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report third quarter 2022 financial results and provide a corporate update.

To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

ANNUNCIO PUBBLICITARIO

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com